{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:30:54Z","timestamp":1784835054962,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.amjmed.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T11:19:02Z","timestamp":1571051942000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2019.09.002_bib0001","article-title":"Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes","author":"Johansen","year":"2018","journal-title":"Diabetes Metab"},{"issue":"43","key":"10.1016\/j.amjmed.2019.09.002_bib0002","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.3748\/wjg.v22.i43.9488","article-title":"Nonalcoholic fatty liver disease - A multisystem disease?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.cgh.2018.11.037","article-title":"Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham Heart Study","volume":"17","author":"Fricker","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0004","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevi\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","article-title":"The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"239","author":"Al Rifai","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.amjmed.2019.09.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.001979","article-title":"Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease","volume":"8","author":"Gran\u00e9r","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0007","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.109.882241","article-title":"Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community","volume":"121","author":"Schnabel","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjmed.2019.09.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177684","article-title":"Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE)","volume":"12","author":"AlBadri","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.amjmed.2019.09.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000782","article-title":"Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort","volume":"5","author":"Gong","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0010","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ejhf.1294","article-title":"The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2147\/TCRM.S94955","article-title":"Association of epicardial adipose tissue thickness and inflammation parameters with CHA2DS2-VASASc score in patients with nonvalvular atrial fibrillation","volume":"11","author":"Akdag","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0014","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmg.2018.11.031","article-title":"Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction [e-pub ahead of print]","author":"Kanagala","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0016","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jacc.2015.06.1314","article-title":"Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands","volume":"66","author":"Vermond","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchf.2016.09.016","article-title":"Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation","volume":"5","author":"Pandey","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","article-title":"Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"5","author":"Sartipy","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0019","first-page":"546","article-title":"Relationship between exercise induced elevation of left ventricular filling pressure and exercise intolerance in patients with atrial fibrillation","volume":"13","author":"Chen","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cardfail.2017.04.002","article-title":"Prevalence and predictors of early heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation","volume":"23","author":"Meluzin","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/CIRCULATIONAHA.117.030093","article-title":"High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea","volume":"137","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0022","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amjmed.2019.09.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201499","article-title":"Association of serum concentrations of irisin and the adipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients","volume":"13","author":"Kaneda","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCEP.111.000104","article-title":"Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation","volume":"6","author":"Fukui","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ijcard.2016.11.194","article-title":"HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin","volume":"228","author":"Fax\u00e9n","year":"2017","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.amjmed.2019.09.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162473","article-title":"Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease","volume":"11","author":"Fracanzani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0027","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0028","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MEG.0b013e32834f15dd","article-title":"The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population","volume":"24","author":"Zelber-Sagi","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.amjmed.2019.09.002_bib0029","doi-asserted-by":"crossref","first-page":"e3050","DOI":"10.1002\/dmrr.3050","article-title":"Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes","volume":"34","author":"Cernea","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0030","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1309\/6VJ4DWGYDU0XYJ8Q","article-title":"Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease","volume":"127","author":"Manco","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0031","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1148\/radiol.2019181793","article-title":"Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET\/CT","volume":"291","author":"Vita","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0032","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/echo.14229","article-title":"Interatrial septal fat thick-ness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation","volume":"36","author":"Mahfouz","year":"2019","journal-title":"Echocardiography"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0033","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20130298","article-title":"Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study","volume":"126","author":"Kocabay","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0034","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.clinre.2017.08.001","article-title":"The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis","volume":"41","author":"Wijarnpreecha","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/liv.14018","article-title":"Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"39","author":"Whitsett","year":"2019","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.amjmed.2019.09.002_bib0036","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"50","author":"Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.03.027","article-title":"Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction","volume":"272","author":"Chung","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.amjmed.2019.09.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135329","article-title":"Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes","volume":"10","author":"Mantovani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0039","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1177\/0300060518782780","article-title":"Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance","volume":"46","author":"Zhang","year":"2018","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.amjmed.2019.09.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173398","article-title":"Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure","volume":"12","author":"Valbusa","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0041","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/TP.0b013e31825f0f97","article-title":"Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation","volume":"94","author":"Dowsley","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0042","doi-asserted-by":"crossref","first-page":"36783","DOI":"10.1038\/srep36783","article-title":"Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"6","author":"Dong","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0043","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1536\/ihj.14-261","article-title":"Successful weight reduction improves left ventricular diastolic function and physical performance in severe obesity","volume":"56","author":"Fenk","year":"2015","journal-title":"Int Heart J"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0044","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ahj.2015.07.026","article-title":"Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial","volume":"170","author":"Alonso","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0045","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0046","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00464-016-5082-8","article-title":"The effects of bariatric surgeries on nonalcoholic fatty liver disease","volume":"31","author":"Aldoheyan","year":"2017","journal-title":"Surg Endosc"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0047","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of weight reduction and cardiometa-bolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial","volume":"310","author":"Abed","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0048","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/obr.12707","article-title":"Effects of intentional weight loss in patients with obesity and heart failure: a systematic review","volume":"19","author":"McDowell","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0049","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/ATVBAHA.107.160663","article-title":"Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3\/IFN-beta pathway in macrophages","volume":"28","author":"Abe","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0050","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jb\/mvp035","article-title":"Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation","volume":"145","author":"Maeda","year":"2009","journal-title":"J Biochem"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0051","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.dld.2011.12.013","article-title":"Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-\u03b1-lowering property","volume":"44","author":"Hyogo","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0052","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijcard.2018.06.106","article-title":"Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue","volume":"274","author":"Parisi","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0053","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4238\/2013.September.10.5","article-title":"Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation","volume":"12","author":"Li","year":"2013","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0054","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2007.09.063","article-title":"Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials","volume":"51","author":"Fauchier","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2169\/internalmedicine.46.0021","article-title":"Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure","volume":"46","author":"Okura","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0056","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ejhf.1183","article-title":"Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0057","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0058","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2017.09.025","article-title":"Metformin improves obesity-associated inflammation by altering macrophages polarization","volume":"461","author":"Jing","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0059","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/dc17-0589","article-title":"Effects of liraglutide on weight loss, fat distribution, and \u03b2-cell function in obese subjects with prediabetes or early type 2 diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0061","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0062","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.repc.2018.08.010","article-title":"Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients","volume":"38","author":"Ziyrek","year":"2019","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0063","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-014-0123-x","article-title":"Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies","volume":"13","author":"Chang","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0064","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-10-0624","article-title":"Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes","volume":"163","author":"Andersson","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0066","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0067","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00380-018-01327-4","article-title":"Liraglutide suppresses atrial electrophysiological changes","volume":"34","author":"Nakamura","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0068","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0069","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0071","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0072","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0073","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/CBM-170157","article-title":"Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study","volume":"20","author":"Deng","year":"2017","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0074","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2019.09.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12284","article-title":"Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits","volume":"35","author":"Liu","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0076","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FJC.0000000000000397","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 prevents development of heart failure with preserved ejection fraction; inhibition of Wnt-\u03b2-catenin signaling as a possible mechanism","volume":"68","author":"Kamimura","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0077","first-page":"140","article-title":"Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study","volume":"3","author":"Pallisgaard","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0078","first-page":"401","article-title":"Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study","volume":"65","author":"Ordu","year":"2010","journal-title":"Acta Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2019.09.002_bib0079","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12872-017-0531-4","article-title":"Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.amjmed.2019.09.002_bib0080","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1007\/s00125-010-1756-2","article-title":"Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals","volume":"53","author":"Zanchi","year":"2010","journal-title":"Diabetologia"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319308435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319308435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:18:25Z","timestamp":1757582305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934319308435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0002934319308435"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.09.002","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}